Panel Discussion: Geopolitics, trade and trust The forces reshaping India Pharma Inc

Panellists Speaker in this video:
○ Ms Lakshmipriya Nair, Assistant Editor, Express Pharma (Moderator)
○ Mr Ravi Bhardwaj, Corporate Quality Head, Ind Swift Laboratories
○ Mr Vishnu Mirge, AVP – Site Head, Sun Pharmaceutical Industries
○ Dr Pardeep Agnihotri, Sr GM – Corporate Regulatory Affairs, CEPH Lifesciences
○ Mr Yogesh Sharma, Head-Quality & Compliance, Sun Pharmaceutical Industries
○ Mr Saurabh Sharma, GM-Supply Chain, Sentiss Pharma
○ Dr Saurabh Pandey, Cluster Lead-API Manufacturing-Toansa-Punjab, Sun Pharmaceutical Industries
○ Mr Prafulla Padhy, Head – Supply Chain Management, Fresenius Kabi Oncology

Key Highlights:
[1] Supply chain, manufacturing, and quality have become strategic business functions, driving resilience and sustainable growth.

[2] Geopolitical uncertainties and supply disruptions are reshaping pharma strategies, with greater focus on risk management and business continuity.

[3] Quality and compliance have moved to the boardroom, emphasising data integrity, inspection readiness, and a strong quality culture.

[4] AI, digitalisation, and Industry 4.0 are enabling predictive, data-driven decision-making across manufacturing and quality operations.

[5] Reducing dependence on China for APIs requires stronger domestic manufacturing, supplier diversification, and policy support.

[6] Innovation, ESG, and workforce capability will be key drivers of the industry’s next phase of growth.

[7] India’s future pharma leadership will depend on balancing affordability, compliance, resilience, and innovation.